Disease

Enterobacteriaceae Infections

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 1, 2026 · JOURNAL ARTICLE

Activity of Aztreonam-avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa causing infections in patients hospitalized in hematology, oncology, and transplant units from United States medical centres (2019-2024).

Diagnostic Microbiology and Infectious Disease

In vitro susceptibility surveillance from a large multicenter collection in immunocompromised patients; establishes baseline resistance patterns and comparative agent activity but lacks clinical outcome data, treatment efficacy, or validation in patient populations.

PreliminaryTodd Riccobene Cancer Enterobacteriaceae Infections

Reported

Sample size – Enterobacterales2407

Sample size – Pseudomonas aerugin…485

Aztreonam-avibactam susceptibilit…99.9%

JUL 26, 2026 · JOURNAL ARTICLE

Efficacy of the NMIC-150 system in identifying extended-spectrum beta-lactamases in clinical isolates.

Diagnostic Microbiology and Infectious Disease

A single-centre diagnostic accuracy study of moderate size with sound methodology but surrogate endpoints (categorical agreement, MIC prediction) rather than clinical outcomes, showing the NMIC-150 system performs comparably to reference broth microdilution for ESBL detection.

PromisingWhole Genome Sequencing Jingxin Ma Liyan Ma

Reported

Categorical and essential agreeme…over 90%

Sample size278

ESBL definition≥eight-fold reduction in MIC of 3GCs with c…